EX 108
Alternative Names: EX-108Latest Information Update: 09 Oct 2023
Price :
$50 *
At a glance
- Originator Guangzhou Excelmab
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastric cancer; Triple negative breast cancer
Most Recent Events
- 20 Sep 2023 Guangzhou ExcelMab announces intention to submit BLA of EX 108 for Triple-negative breast cancer and Gastric cancer in USA and China, in mid-2025 (Guangzhou ExcelMab pipeline, September 2023)
- 20 Sep 2023 Guangzhou ExcelMab announces intention to submit IND application for Triple-negative breast cancer and Gastric cancer in USA and China, by the end of 2023 (Guangzhou ExcelMab pipeline, September 2023)
- 20 Sep 2023 Guangzhou ExcelMab plans a phase II trial of EX 108 for Triple-negative breast cancer and Gastric cancer in USA and China, in mid-2025 (Guangzhou ExcelMab pipeline, September 2023)